Skip to main content
SpringerLink
Log in

MEK-Inhibition verbessert Therapie mit BRAF-Hemmern bei malignem Melanom

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

Wie schneidet die Kombination von Vemurafenib mit Cobimetinib gegenüber Vemurafenib allein beim progressionsfeien Überleben ab?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Robert Bublak

Authors
  1. Robert Bublak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bublak, R. MEK-Inhibition verbessert Therapie mit BRAF-Hemmern bei malignem Melanom. hautnah dermatologie 31, 20 (2015). https://doi.org/10.1007/s15012-015-1747-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-015-1747-6

Search

Navigation